New uses of oubain and oubain-like molecules in apoptosis related pathologies
CA 2273699 A1 · Owner: Corporation Du Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal · Inventors: Orlov, Sergei N.; Tremblay, Johanne; Hamet, Pavel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Longterm elevation of the intracellular Na /K+ ratio inhibits macromolecule synthesis and, proliferation in the majority of cell types studied so far including vascular , smooth muscle cells (VSMC). We report here that inhibition of the Na+,K+ pump in VSMC by ouabain or 1 hr, preincubation in K+-depleted medium attenuated apoptosis triggered by serum withdrawal, staurosporine or okadaic acid. In the absence of ouabain both DNA degradation , and caspase-3, activation in VSMC undergoing apoptosis were insensitive to modification of the extracellular, Na+/K+ ratio as well as to hyperosmotic cell shrinkage. In contrast protection of VSMC from, apoptosis by ouabain was abolished under …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 3, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 3, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 3, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.